Product Description: Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Valentinis B, et, al. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling. Int J Mol Sci. 2019 Sep 12;20(18):4511. /[2]Gregorc V, et, al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19(6):799-811.
CAS Number: 1960461-99-7
Molecular Weight: N/A
Research Area: Cancer
Solubility: H2O
Target: TNF Receptor
English
Deutsch
